Loading...

NOXXON Pharma

DB:0N6
Snowflake Description

Slightly overvalued with concerning outlook.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0N6
DB
€8M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
  • NOXXON Pharma has significant price volatility in the past 3 months.
0N6 Share Price and Events
7 Day Returns
3.9%
DB:0N6
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-
DB:0N6
-9.2%
DE Biotechs
-6.7%
DE Market
0N6 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NOXXON Pharma (0N6) 3.9% -13% -14.1% - - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • No trading data on 0N6.
  • No trading data on 0N6.
Price Volatility
0N6
Industry
5yr Volatility vs Market

Value

 Is NOXXON Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of NOXXON Pharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for NOXXON Pharma.

DB:0N6 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:0N6
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 30%) (36.88%))
1.557
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.56
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.557 * 5.96%)
9.51%

Discounted Cash Flow Calculation for DB:0N6 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for NOXXON Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:0N6 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 9.51%)
2019 -4.60 Analyst x1 -4.20
2020 13.30 Analyst x1 11.09
2021 19.95 Est @ 50.02% 15.19
2022 26.95 Est @ 35.09% 18.74
2023 33.59 Est @ 24.63% 21.33
2024 39.41 Est @ 17.31% 22.85
2025 44.21 Est @ 12.18% 23.41
2026 48.01 Est @ 8.6% 23.21
2027 50.93 Est @ 6.09% 22.48
2028 53.13 Est @ 4.33% 21.42
Present value of next 10 years cash flows €175.52
DB:0N6 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €53.13 × (1 + 0.23%) ÷ (9.51% – 0.23%)
€573.75
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €573.75 ÷ (1 + 9.51%)10
€231.31
DB:0N6 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €175.52 + €231.31
€406.83
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €406.83 / 10.06
€40.45
DB:0N6 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:0N6 represents 0.98267x of ENXTPA:ALNOX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.98267x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 40.45 x 0.98267
€39.75
Value per share (EUR) From above. €39.75
Current discount Discount to share price of €0.74
= -1 x (€0.74 - €39.75) / €39.75
98.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price NOXXON Pharma is available for.
Intrinsic value
>50%
Share price is €0.74 vs Future cash flow value of €39.75
Current Discount Checks
For NOXXON Pharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • NOXXON Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • NOXXON Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NOXXON Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NOXXON Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0N6 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-2.70
ENXTPA:ALNOX Share Price ** ENXTPA (2019-04-18) in EUR €0.75
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NOXXON Pharma.

DB:0N6 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ALNOX Share Price ÷ EPS (both in EUR)

= 0.75 ÷ -2.70

-0.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NOXXON Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • NOXXON Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does NOXXON Pharma's expected growth come at a high price?
Raw Data
DB:0N6 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.28x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NOXXON Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NOXXON Pharma's assets?
Raw Data
DB:0N6 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €-1.82
ENXTPA:ALNOX Share Price * ENXTPA (2019-04-18) in EUR €0.75
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:0N6 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ALNOX Share Price ÷ Book Value per Share (both in EUR)

= 0.75 ÷ -1.82

-0.41x

* Primary Listing of NOXXON Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NOXXON Pharma has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
X
Value checks
We assess NOXXON Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. NOXXON Pharma has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NOXXON Pharma expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.4%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is NOXXON Pharma expected to grow at an attractive rate?
  • Unable to compare NOXXON Pharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare NOXXON Pharma's earnings growth to the Germany market average as no estimate data is available.
  • NOXXON Pharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:0N6 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0N6 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 16.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0N6 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0N6 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 0 1
2022-12-31 26 1
2021-12-31 0 1
2020-12-31 26 21 1
2019-12-31 0 -5 1
DB:0N6 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -11
2018-09-30 0 -9
2018-06-30 0 -4 -7
2018-03-31 0 -4 -6
2017-12-31 0 -4 -5
2017-09-30 0 -5 -5
2017-06-30 0 -6 -5
2017-03-31 0 -7 -8
2016-12-31 0 -9 -11
2016-09-30 0 -10 -13
2016-06-30 0 -12 -16
2016-03-31 0 -13 -16

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if NOXXON Pharma is high growth as no earnings estimate data is available.
  • NOXXON Pharma's revenue is expected to grow by 16.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0N6 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from NOXXON Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0N6 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
DB:0N6 Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -2.70
2018-09-30 -2.88
2018-06-30 -3.12
2018-03-31 -2.84
2017-12-31 -2.54
2017-09-30 -2.55
2017-06-30 -2.64
2017-03-31 -4.51
2016-12-31 -6.71
2016-09-30 -8.29
2016-06-30 -9.82
2016-03-31 -11.79

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NOXXON Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess NOXXON Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NOXXON Pharma has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NOXXON Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NOXXON Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NOXXON Pharma does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare NOXXON Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NOXXON Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
NOXXON Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NOXXON Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0N6 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.38 -10.73 2.49 2.21
2018-09-30 0.22 -9.04 2.62 2.26
2018-06-30 0.07 -7.21 2.71 2.35
2018-03-31 0.15 -6.30 2.66 2.37
2017-12-31 0.23 -5.39 2.61 2.38
2017-09-30 0.36 -5.10 2.72 2.72
2017-06-30 0.48 -4.96 2.86 3.03
2017-03-31 0.47 -7.85 3.48 3.84
2016-12-31 0.47 -10.75 4.10 4.66
2016-09-30 0.35 -13.46 5.13 5.39
2016-06-30 0.23 -16.18 6.16 6.12
2016-03-31 0.13 -16.14 6.78 6.46
2015-12-31 0.04 -16.10 7.39 6.80
2014-12-31 0.03 -13.80 3.69 9.31

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NOXXON Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if NOXXON Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NOXXON Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess NOXXON Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NOXXON Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NOXXON Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NOXXON Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NOXXON Pharma's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • NOXXON Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NOXXON Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • NOXXON Pharma has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NOXXON Pharma Company Filings, last reported 3 months ago.

DB:0N6 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31
2018-09-30 -4.36 2.78 0.80
2018-06-30 -4.36 2.78 0.80
2018-03-31 -4.36 2.78 0.80
2017-12-31 -3.92 2.61 0.62
2017-09-30 -3.92 2.61 0.62
2017-06-30 -2.45 1.57 1.12
2017-03-31 -2.45 1.57 1.12
2016-12-31 -2.48 2.94 2.21
2016-09-30 -2.48 2.94 2.21
2016-06-30 -11.78 11.08 1.82
2016-03-31 -11.78 11.08 1.82
2015-12-31 -7.03 8.88 4.09
2014-12-31 -6.24 6.32 1.53
  • NOXXON Pharma has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if NOXXON Pharma's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NOXXON Pharma has less than a year of cash runway based on current free cash flow.
  • NOXXON Pharma has less than a year of cash runway if free cash flow continues to reduce at historical rates of -54% each year.
X
Financial health checks
We assess NOXXON Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NOXXON Pharma has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NOXXON Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NOXXON Pharma dividends.
If you bought €2,000 of NOXXON Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NOXXON Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NOXXON Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0N6 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0N6 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NOXXON Pharma has not reported any payouts.
  • Unable to verify if NOXXON Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NOXXON Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NOXXON Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NOXXON Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NOXXON Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NOXXON Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NOXXON Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Aram Mangasarian
COMPENSATION €344,311
AGE 48
TENURE AS CEO 3.8 years
CEO Bio

Dr. Aram Mangasarian has been the Chief Executive Officer and Member of Executive Board at NOXXON Pharma AG since July 1, 2015 and served as its has been Chief Business Officer since May 18, 2010 and serves as its Member of Executive Board. Dr. Mangasarian is responsible for corporate and business development activities for NOXXON. He has more than 10 years of business development and strategic planning experience within the biotechnology and pharmaceutical industry. He served as Vice President of Business Development of Novexel SA. Dr. Mangasarian joined Novexel SA group from another French firm, ExonHit Therapeutics SA, a publicly traded French drug discovery and development company, where he spent over five years in business development, most recently as Vice President of Business Development. During this time, Dr. Mangasarian identified strategic partners, negotiated alliances and was responsible for marketing and sales of research products. He led the team that built strategic alliances and negotiated research agreements with a number of pharmaceutical companies. A key part of his role at ExonHit was the development of commercialization strategies. Dr. Mangasarian concluded a number of licensing and research agreements and prepared Novexel SA towards IPO. During his time in the laboratory of Didier Trono, he led two different teams in research projects in virology. He has contributed to several scientific publications including Nature Cell Biology and the Journal of Virology. Prior to ExonHit, he held a postdoctoral fellowship at The University of Geneva Medical School in the Department of Genetics and Microbiology from 1997 to 1999. He holds B.S. BioChemistry, Molecular Biology, English from University of Wisconsin-Madison in the year 1987-1992. As graduate of the University of California, San Diego, he earned his PhD in the Department of Biology by conducting research on HIV in the year 1992-1997. He holds an MBA in Business, from Insead in the year 1999.

CEO Compensation
  • Aram's compensation has increased whilst company is loss making.
  • Aram's remuneration is lower than average for companies of similar size in Germany.
Management Team

Aram Mangasarian

TITLE
CEO & Member of Management Board
COMPENSATION
€344K
AGE
48
TENURE
3.8 yrs

Jarl Jungnelius

TITLE
Chief Medical Officer & Member of Management Board
AGE
67
TENURE
1.9 yrs
Board of Directors Tenure

Average tenure and age of the NOXXON Pharma board of directors in years:

3.3
Average Tenure
60
Average Age
  • The tenure for the NOXXON Pharma board of directors is about average.
Board of Directors

Don deBethizy

TITLE
Chairman of Supervisory Board
COMPENSATION
€11K
AGE
68
TENURE
1.6 yrs

Bertram Köhler

TITLE
Vice Chairman of the Supervisory Board
AGE
46

Hubert Birner

TITLE
Member of Supervisory Board
AGE
52
TENURE
3.8 yrs

Walter Wenninger

TITLE
Member of Supervisory Board
COMPENSATION
€12K
AGE
80
TENURE
3.3 yrs

Jan Burger

TITLE
Member of Nox-A12 Advisory Board

Kai Hübel

TITLE
Member of Nox-A12 Advisory Board

Ibrahim Yakoub-Agha

TITLE
Member of Nox-A12 Advisory Board

Martin Brown

TITLE
Member of Nox-A12 Advisory Board

Wolfgang Wick

TITLE
Member of Nox-A12 Advisory Board

Hans-Joachim Anders

TITLE
Member of Nox-E36 Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess NOXXON Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NOXXON Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase IIa clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.

Details
Name: NOXXON Pharma N.V.
0N6
Exchange: DB
Founded: 1997
€7,542,816
10,057,088
Website: http://www.noxxon.com
Address: NOXXON Pharma N.V.
Max-Dohrn-Strasse 8-10,
Berlin,
Berlin, 10589,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ALNOX Ordinary Shares Euronext Paris FR EUR 30. Sep 2016
DB 0N6 Ordinary Shares Deutsche Boerse AG DE EUR 30. Sep 2016
BST 0N6 Ordinary Shares Boerse-Stuttgart DE EUR 30. Sep 2016
Number of employees
Current staff
Staff numbers
10
NOXXON Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:53
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/04/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.